Big Molecule Watch
December 29, 2016

Coherus Files Petitioner’s Reply in Three IPRs Relating to Abbvie’s Humira (adalimumab)

Yesterday, Coherus filed its Petitioner Reply in IPR2016-00188 (U.S. Patent 9.017,680), IPR2016-00189 (9,073,987), and IPR2016-00172 (U.S. Patent 8,889,135).  Each of these patents is owned by Abbvie, and, according to the documents filed in these IPRs, each relates to Humira® (adalimumab).

We have added these Replies to our IPR Tracker Page, where we post selected important filings in IPRs related to biologics.